市场调查报告书
商品编码
1403524
到 2030 年双能量 X 射线吸收测量市场预测:按类型、技术、应用、最终用户和地区进行的全球分析Dual-energy X-ray Absorptiometry Market Forecasts to 2030 - Global Analysis By Type, Technology, Application, End User and by Geography |
根据 Stratistics MRC 的数据,2023 年全球双能量 X 射线吸收仪(DEXA)市场规模为 6,1952 万美元,预测期内复合年增长率为 10.0%,到 2030 年将达到 1,20727 万美元。达到美元。
使用双能量 X 射线检测法(DEXA) 可以准确、非侵入性地测量骨骼密度(BMD) 和身体组成。 DEXA 透过使用具有两种不同能量水平的低剂量 X 射线束来区分骨骼、脂肪和瘦肉组织,提供有关个人骨骼健康和整体身体组成的精确资讯。 DEXA 测试通常用于评估骨质疏鬆症,有助于确定骨折风险和骨矿物质流失。
根据国际骨质疏鬆症基金会的数据,50 岁以上的女性和男性中,约有三分之一和五分之一患有骨质疏鬆症。该组织也估计,美国、欧洲和日本有超过 7,500 万例与骨质疏鬆症有关。
随着世界老年人口的增加,与老龄化相关的骨质流失或骨质疏鬆症变得越来越普遍。 DEXA 对于诊断这种虚弱至关重要,因为它是一种重要的诊断工具,可进行快速介入以避免骨折和相关併发症。此外,定期 DEXA 检测对于高龄化人口的持续健康管理是必要的,并鼓励儘早采取老年保健措施。
医疗机构可能面临财务困难,不仅因为 DEXA 设备的初始资本支出,而且还因为持续的维护成本。这些成本是由复杂的技术和确保准确性所需的持续校准所驱动的。此外,这种经济因素强调了医疗保健规划中财务考虑的必要性,并可能阻止 DEXA 的广泛采用,特别是在资源匮乏的环境中。
除了临床诊断之外,DEXA 还可用于研究目的,是评估药物如何影响骨骼健康的有用工具。此外,DEXA 能够追踪骨骼成分和密度的变化,从而能够更有效、更有针对性地治疗骨质疏鬆症等疾病,为药物开发提供重要资讯。製药公司和学术机构之间的合作提供了该领域进一步研究的机会。
新的替代技术和竞争形势的变化对 DEXA 市场构成威胁。 DEXA 在市场上的主导地位受到定量电脑断层扫描 (QCT) 和周边定量电脑断层扫描 (pQCT) 等竞争诊断方式的威胁。此外,随着替代技术开拓市场并吸引资本和注意力从传统 DEXA 系统转移,市场占有率份额和普及可能会受到影响。
双能量 X 射线检测法(DEXA) 市场受到了 COVID-19 爆发的严重影响。由于医疗保健服务中断、为应对流行病相关挑战而重新分配资源以及安全问题加剧,DEXA 扫描等常规诊断程序有所减少。此外,由于多种因素的综合作用,DEXA 技术的采用已暂时停滞,包括患者就诊医疗机构的次数减少、非紧急预约的延迟以及医疗保健预算的财务限制。但这场大流行也凸显了预防性照护的价值,只要卫生系统在疫情后復原期间优先考虑常规筛检和诊断程序,DEXA 就有可能捲土重来。
轴向 DEXA骨质密度检测设备预计将占据双能量 X 射线检测法(DEXA) 的最大市场占有率。这些设备主要用于评估髋部和脊椎的骨骼密度,这是评估骨折和骨质疏鬆症风险的重要区域。轴向 DEXA 扫描可提供有关骨骼健康的高度准确且全面的资讯,帮助医生诊断骨质疏鬆症等疾病并评估治疗效果。此外,轴向配置是各种医疗机构中临床医生的首选,因为它们可以对骨骼的中心区域进行彻底检查。随着骨质疏鬆症变得越来越普遍,骨骼健康变得越来越重要,轴向 DEXA骨质密度检测设备对于疾病管理和预防性护理始终至关重要。
在身体组成分析领域,双能量X射线检测法(DEXA)市场预计将以最高的复合年增长率成长。人们越来越认识到身体组成对整体健康、健身和疾病预防的影响,从而推动了先进诊断工具市场的发展。除了传统的骨骼密度测试之外,身体组成分析还可以对去脂体重、脂肪分布和其他重要因素进行全面分析。此外,科技对于解决全球对肥胖、代谢紊乱和导致肌肉萎缩的疾病的担忧至关重要。
占据最大份额的北美地区继续保持在双能量X射线吸收仪(DEXA)市场的主导地位。特别是在美国,医疗保健产业十分成熟且技术先进,在医学研究、最先进的设备和庞大的基础设施方面投入了大量资金。此外,高水准的医疗保健支出、强有力的法规环境以及对技术创新的持续关注也凸显了该地区的优势。因此,以美国为中心的北美地区持续对全球医疗保健产业的发展产生重大影响。
预计亚太地区在预测期内的复合年增长率最高。医疗保健基础设施投资的增加、高龄化和不断变化的医疗需求以及医疗意识的提高是促成这一显着增长的因素。在製药、医疗技术和医疗保健服务方面领先的国家是中国、印度和日本。此外,该地区对数位健康解决方案的关注、鼓励的政府倡议等使亚太地区成为医疗保健转型的领先中心,对该市场的年复合成长率的增长做出了重大贡献。
According to Stratistics MRC, the Global Dual-energy X-ray Absorptiometry (DEXA) Market is accounted for $619.52 million in 2023 and is expected to reach $1207.27 million by 2030 growing at a CAGR of 10.0% during the forecast period. Bone mineral density (BMD) and body composition can be measured with accuracy and without invasiveness using dual-energy X-ray absorptiometry (DEXA). DEXA provides precise information about an individual's skeletal health and overall body composition by using low-dose X-ray beams at two different energy levels to differentiate between bone, fat, and lean tissue. DEXA scans are frequently used to evaluate osteoporosis and are useful in determining fracture risk and bone mineral loss.
According to the International Osteoporosis Foundation, around one in three women and one in five men over the age of 50 are suffering from osteoporosis. The organization also estimated that over 75 million patients are associated with osteoporosis in the U.S., Europe, and Japan.
Age-related bone loss, or osteoporosis, is becoming more common as the world's senior population grows. DEXA is essential for diagnosing this vulnerability because it is a critical diagnostic tool that enables prompt interventions to avoid fractures and associated complications. Additionally, regular DEXA scans are required for the ongoing health management of the aging population, which encourages an early approach to senior healthcare.
Healthcare facilities may face financial difficulties with the initial capital expenditure for DEXA equipment as well as continuing maintenance costs. The cost of all this is influenced by the complex technology and constant calibration needed to ensure accuracy. Furthermore, this financial factor highlights the need for financial considerations in healthcare planning and may prevent DEXA from being widely adopted, particularly in settings where resources are scarce.
Beyond clinical diagnostics, DEXA can be used in research applications and is a useful tool for evaluating how medications affect bone health. Moreover, its function in tracking alterations in the composition and density of bone offers vital information for medication development, enabling more effective and focused treatments for diseases like osteoporosis. Opportunities for more research in this area are provided by partnerships between pharmaceutical companies and academic institutions.
Emerging alternative technologies and changing competitive landscapes pose threats to the DEXA market. The dominance of DEXA in the market is threatened by competing diagnostic modalities like quantitative computed tomography (QCT) and peripheral quantitative computed tomography (pQCT). Additionally, market share and adoption rates may be impacted if ongoing developments in alternative technologies draw capital and attention away from conventional DEXA systems.
The market for dual-energy X-ray absorptiometry (DEXA) has been greatly impacted by the COVID-19 pandemic. Routine diagnostic procedures, such as DEXA scans, have decreased as a result of disruptions to healthcare services, the reallocation of resources to address pandemic-related challenges, and increased safety concerns. Furthermore, the adoption of DEXA technology has temporarily stalled due to a combination of factors, including fewer patient visits to healthcare facilities, delays in non-urgent medical appointments, and financial constraints on healthcare budgets. But the pandemic has also highlighted the value of preventive healthcare, which may present prospects for DEXA's comeback as long as healthcare systems give regular screenings and diagnostic procedures top priority during the post-pandemic recovery period.
It is projected that axial DEXA bone densitometers will command the largest market share in dual-energy X-ray absorptiometry (DEXA). These instruments are mainly used to assess the bone mineral density in the hip and spine, which are important regions to assess the risk of fractures and osteoporosis. Axial DEXA scans help physicians diagnose diseases like osteoporosis and evaluate the efficacy of treatments by giving them extremely precise and comprehensive information about bone health. Moreover, clinicians in a variety of healthcare settings prefer the axial configuration because it enables a thorough examination of central skeletal sites. As osteoporosis becomes more common and bone health becomes more important, axial DEXA bone densitometers will always be essential for managing diseases and providing preventive care.
The market for dual-energy X-ray absorptiometry (DEXA) is expected to grow at the highest CAGR in the body composition analysis segment. The market for advanced diagnostic tools has been driven by growing awareness of the influence of body composition on overall health, fitness, and disease prevention. Beyond conventional bone density tests, body composition analysis offers a thorough analysis of lean muscle mass, fat distribution, and other important factors. Additionally, in order to address the global concerns surrounding obesity, metabolic disorders, and conditions that cause muscle wasting, technology is essential.
With the largest share, North America has continued to hold a dominant position in the dual-energy X-ray absorptiometry (DEXA) market. Particularly in the United States, the healthcare industry is well-established and technologically sophisticated, with large expenditures made in medical research, state-of-the-art equipment, and a vast infrastructure. Furthermore, the prominence of the region is emphasized by the high level of healthcare spending, the strong regulatory environment, and the ongoing emphasis on innovation. Because of this, North America-led by the United States-continues to have a significant influence on how the global healthcare sector develops.
The Asia-Pacific region is expected to have the highest CAGR over the projected period. Growing investments in healthcare infrastructure, an aging population with evolving healthcare needs, and growing healthcare awareness are all factors contributing to this notable growth. Leading nations in the advancement of pharmaceuticals, medical technology, and healthcare services are China, India, and Japan. Additionally, the region's emphasis on digital health solutions, along with encouraging government initiatives, positions Asia-Pacific as a major hub for the changing healthcare landscape and contributes significantly to the market's rising compound annual growth rate.
Some of the key players in Dual-energy X-ray Absorptiometry (DEXA) market include Osteometer Meditech Inc, Medilink International, GE Healthcare, Shenzhen XRAY Electric Co., Ltd., BeamMed Ltd, Furuno Electric Co., Ltd., Hologic, Inc., Scanflex Healthcare AB, Medonica Co., Ltd, Fonar Corporation and Swissray Medical AG.
In December 2023, GE Healthcare has entered into a distribution agreement with mobile-first clinical surveillance technology provider, AirStrip to expand AirStrip Cardiology and Patient Monitoring solutions in the US. The mobile application from AirStrip enables clinicians to view clinical data on the web and on mobile devices. It connects with cardiac rhythm strips and 12-lead ECGs, allowing clinicians to monitor numerous patients at the same time and can receive STEMI notifications.
In October 2023, MediLink Therapeutics, announced today that it has entered into a strategic research collaboration and worldwide license agreement with BioNTech SE, a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, on the development of a next-generation antibody-drug conjugate candidate ("ADC"), against Human Epidermal Growth Factor Receptor 3 (HER3).
In September 2023, Hologic Inc. and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions. CEM is a highly sensitive and relatively low-cost breast imaging modality that combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions.